JP2019512464A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512464A5 JP2019512464A5 JP2018543153A JP2018543153A JP2019512464A5 JP 2019512464 A5 JP2019512464 A5 JP 2019512464A5 JP 2018543153 A JP2018543153 A JP 2018543153A JP 2018543153 A JP2018543153 A JP 2018543153A JP 2019512464 A5 JP2019512464 A5 JP 2019512464A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- chain variable
- variable region
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 24
- 239000002254 cytotoxic agent Substances 0.000 claims description 18
- 229940127089 cytotoxic agent Drugs 0.000 claims description 17
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 230000033581 fucosylation Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 9
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 9
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 9
- 208000026278 immune system disease Diseases 0.000 claims description 9
- 230000002489 hematologic effect Effects 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 8
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 7
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 7
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 150000008267 fucoses Chemical class 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000023328 Basedow disease Diseases 0.000 claims description 4
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 4
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 4
- 208000015023 Graves' disease Diseases 0.000 claims description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000008827 tuberculosis Diseases 0.000 claims description 4
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 3
- 239000012626 DNA minor groove binder Substances 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 102000009490 IgG Receptors Human genes 0.000 claims description 3
- 108010073807 IgG Receptors Proteins 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 3
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical group CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 3
- 239000000824 cytostatic agent Substances 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000000564 macroglobulinemia Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 230000002071 myeloproliferative effect Effects 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims description 2
- 102000046935 human TNFRSF17 Human genes 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 15
- 239000001963 growth medium Substances 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- SQTFKIKSQNCWGJ-KCDKBNATSA-N (2s,3r,4r,5s)-2-fluoro-3,4,5-trihydroxyhexanal Chemical compound C[C@H](O)[C@@H](O)[C@@H](O)[C@H](F)C=O SQTFKIKSQNCWGJ-KCDKBNATSA-N 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 description 7
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022030779A JP2022069488A (ja) | 2016-02-17 | 2022-03-01 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2023216464A JP2024019677A (ja) | 2016-02-17 | 2023-12-22 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662296594P | 2016-02-17 | 2016-02-17 | |
| US62/296,594 | 2016-02-17 | ||
| US201662396084P | 2016-09-16 | 2016-09-16 | |
| US62/396,084 | 2016-09-16 | ||
| PCT/US2017/018177 WO2017143069A1 (en) | 2016-02-17 | 2017-02-16 | Bcma antibodies and use of same to treat cancer and immunological disorders |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020024261A Division JP2020073605A (ja) | 2016-02-17 | 2020-02-17 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2022030779A Division JP2022069488A (ja) | 2016-02-17 | 2022-03-01 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512464A JP2019512464A (ja) | 2019-05-16 |
| JP2019512464A5 true JP2019512464A5 (cg-RX-API-DMAC7.html) | 2020-03-26 |
| JP7152309B2 JP7152309B2 (ja) | 2022-10-12 |
Family
ID=59562012
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543153A Active JP7152309B2 (ja) | 2016-02-17 | 2017-02-16 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2020024261A Pending JP2020073605A (ja) | 2016-02-17 | 2020-02-17 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2022030779A Withdrawn JP2022069488A (ja) | 2016-02-17 | 2022-03-01 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2023216464A Pending JP2024019677A (ja) | 2016-02-17 | 2023-12-22 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020024261A Pending JP2020073605A (ja) | 2016-02-17 | 2020-02-17 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2022030779A Withdrawn JP2022069488A (ja) | 2016-02-17 | 2022-03-01 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
| JP2023216464A Pending JP2024019677A (ja) | 2016-02-17 | 2023-12-22 | 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US20190194338A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3416687A4 (cg-RX-API-DMAC7.html) |
| JP (4) | JP7152309B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102816905B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN116063503A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017219747B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018016697A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3011900A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1259075A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL311107A (cg-RX-API-DMAC7.html) |
| MA (1) | MA44254A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2018009700A (cg-RX-API-DMAC7.html) |
| SG (2) | SG10202007836WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017143069A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3011900A1 (en) | 2016-02-17 | 2017-08-24 | Seattle Genetics, Inc. | Bcma antibodies and use of same to treat cancer and immunological disorders |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| CN110914289B (zh) | 2017-05-12 | 2024-05-14 | 克里斯珀医疗股份公司 | 用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途 |
| PE20210666A1 (es) | 2018-05-11 | 2021-03-31 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer |
| US12252541B2 (en) * | 2018-06-26 | 2025-03-18 | Abl Bio Inc. | Anti-BCMA antibody and use thereof |
| DK3823665T5 (da) | 2018-07-19 | 2024-08-19 | Regeneron Pharma | Kimæriske antigenreceptorer med BCMA-specificitet og anvendelser deraf |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| JP2022512968A (ja) | 2018-11-01 | 2022-02-07 | グレイセル・バイオテクノロジーズ（シャンハイ）カンパニー・リミテッド | Ｔ細胞操作のための組成物および方法 |
| CA3123591A1 (en) * | 2018-12-19 | 2020-06-25 | Seagen Inc. | Controlled fucosylation of antibodies |
| SG11202109163YA (en) * | 2019-02-26 | 2021-09-29 | Sorrento Therapeutics Inc | Antigen binding proteins that bind bcma |
| CN121102493A (zh) | 2019-03-21 | 2025-12-12 | 瑞泽恩制药公司 | 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 |
| EA202192975A1 (ru) | 2019-04-30 | 2022-02-01 | Криспр Терапьютикс Аг | Аллогенная клеточная терапия b-клеточных злокачественных новообразований с применением генетически сконструированных т-клеток, нацеливающихся на cd19 |
| WO2020224606A1 (zh) | 2019-05-07 | 2020-11-12 | 亘喜生物科技（上海）有限公司 | 靶向bcma的工程化免疫细胞及其用途 |
| JP7701276B2 (ja) * | 2019-05-31 | 2025-07-01 | メディミューン，エルエルシー | 併用療法 |
| MX2022001065A (es) * | 2019-07-30 | 2022-02-14 | Shanghai Hansoh Biomedical Co Ltd | Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo. |
| CN112409482B (zh) * | 2019-08-20 | 2022-08-26 | 杭州尚健生物技术有限公司 | Bcma抗体 |
| CN120775052A (zh) * | 2019-10-10 | 2025-10-14 | 再凌生物医药(香港)有限公司 | 靶向bcma的具有人猴交叉的人源化单克隆抗体 |
| KR102837521B1 (ko) * | 2020-01-03 | 2025-07-22 | 바이오션, 인코포레이티드 | Bcma에 결합하는 항체 및 이의 용도 |
| CN113248611A (zh) * | 2020-02-13 | 2021-08-13 | 湖南华康恒健生物技术有限公司 | 抗bcma抗体、其药物组合物及应用 |
| KR20230005163A (ko) | 2020-03-26 | 2023-01-09 | 씨젠 인크. | 다발성 골수종 치료 방법 |
| CN115279781B (zh) * | 2020-03-26 | 2025-05-09 | 上海翰森生物医药科技有限公司 | 抗体药物偶联物及其医药用途 |
| US20230173093A1 (en) | 2020-04-10 | 2023-06-08 | Seagen Inc. | Charge variant linkers |
| KR20230104659A (ko) | 2020-11-08 | 2023-07-10 | 씨젠 인크. | 면역 세포 억제제를 이용한 조합-요법 항체 약물 접합체 |
| WO2022198231A1 (en) | 2021-03-18 | 2022-09-22 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| CN117597150A (zh) | 2021-04-20 | 2024-02-23 | 思进公司 | 抗体依赖性细胞毒性的调节 |
| CN117580593A (zh) | 2021-05-28 | 2024-02-20 | 思进公司 | 蒽环霉素抗体结合物 |
| US20250002553A1 (en) | 2021-08-12 | 2025-01-02 | Shanghai Jmt-Bio Technology Co., Ltd. | A GPC3-targeting antibody-interferon a fusion protein and a use thereof |
| WO2023019398A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Bcma targetting antibodies, chimeric antigen receptors, and uses thereof |
| TW202327650A (zh) | 2021-09-23 | 2023-07-16 | 美商思進公司 | 治療多發性骨髓瘤之方法 |
| WO2023076921A1 (en) * | 2021-10-27 | 2023-05-04 | Janssen Biotech, Inc. | Methods for enhanced bcma immunohistochemistry detection in human and monkey tissue |
| WO2023116759A1 (zh) * | 2021-12-22 | 2023-06-29 | 上海君实生物医药科技股份有限公司 | 抗bcma抗体及其用途 |
| CA3254933A1 (en) | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN119548619A (zh) * | 2023-08-10 | 2025-03-04 | 亘喜生物科技（上海）有限公司 | 一种双靶点car-t细胞在治疗系统性红斑狼疮及其他b细胞自身免疫病中的用途 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025090774A1 (en) | 2023-10-24 | 2025-05-01 | Seagen Inc. | Chemotherapeutic compounds and methods of use |
| WO2025149947A1 (en) | 2024-01-12 | 2025-07-17 | Seagen Inc. | Antibody-drug conjugates |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| WO2025160340A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| PL207501B1 (pl) | 1999-08-17 | 2010-12-31 | Apotech R & D Sa | Zastosowanie polipeptydu BCMA oraz przeciwciała skierowanego przeciwko BCMA |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| NZ522700A (en) | 2000-06-16 | 2006-02-24 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| EP1525213B1 (en) | 2001-10-24 | 2012-06-27 | National Jewish Health | Three-dimensional structures of tall-1 and its cognate receptors and modified proteins and methods related thereto |
| AU2003221256A1 (en) * | 2002-02-21 | 2003-09-09 | Biogen Idec Ma Inc. | Use of bcma as an immunoregulatory agent |
| EP2353611B1 (en) | 2002-07-31 | 2015-05-13 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
| WO2005075511A1 (en) | 2004-01-29 | 2005-08-18 | Genentech, Inc. | Variants of the extracellular domain of bcma and uses thereof |
| TWI355389B (en) | 2004-07-30 | 2012-01-01 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide a |
| CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| US8343928B2 (en) | 2005-07-07 | 2013-01-01 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus |
| EP1952150B1 (en) | 2005-11-23 | 2016-12-14 | Genentech, Inc. | Methods and compositions related to b cell assays |
| EP2609932B1 (en) | 2006-12-01 | 2022-02-02 | Seagen Inc. | Variant target binding agents and uses thereof |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| EP2282773B2 (en) | 2008-05-02 | 2025-03-05 | Seagen Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| MX341884B (es) * | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| US20120201823A1 (en) | 2009-10-14 | 2012-08-09 | Schering Corporation | April antagonists and methods of use |
| EP3974453A3 (en) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| SI3461847T1 (sl) | 2010-12-06 | 2021-03-31 | Seagen Inc. | Humanizirana protitelesa proti LIV-1 in njihova uporaba pri zdravljenju raka |
| WO2012118622A1 (en) | 2011-02-19 | 2012-09-07 | Baylor Research Institute | Diagnostic and therapeutic uses for b cell maturation antigen |
| SG194099A1 (en) * | 2011-04-15 | 2013-11-29 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
| US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| WO2012163805A1 (en) * | 2011-05-27 | 2012-12-06 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| JP6694712B2 (ja) * | 2012-11-01 | 2020-05-20 | マックス−デルブルック−セントラム フアー モレキュラーレ メデジン | Ｃｄ２６９（ｂｃｍａ）に対する抗体 |
| JP6061378B2 (ja) * | 2012-11-05 | 2017-01-18 | 株式会社Ｓｃｒｅｅｎホールディングス | 基板処理装置 |
| TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| PL2953972T3 (pl) * | 2013-02-05 | 2021-03-08 | Engmab Sàrl | Metoda wyboru przeciwciał przeciwko bcma |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| ES2731232T3 (es) | 2013-03-15 | 2019-11-14 | Inst Nat Sante Rech Med | Método y composición farmacéutica para su uso en el tratamiento y la predicción del infarto de miocardio |
| CA2945620C (en) * | 2014-04-14 | 2022-12-06 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| MX375800B (es) * | 2014-04-30 | 2025-03-06 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Anticuerpos humanizados contra cd269 (bcma). |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| WO2016064749A2 (en) | 2014-10-20 | 2016-04-28 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
| JP6691113B2 (ja) | 2014-10-29 | 2020-04-28 | シアトル ジェネティックス， インコーポレイテッド | 非フコシル化抗ｃｄ４０抗体の投与量および投与 |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| LT3221357T (lt) | 2014-11-20 | 2020-08-25 | F. Hoffmann-La Roche Ag | Bendros lengvosios grandinės ir naudojimo būdai |
| CN113429485A (zh) | 2014-12-05 | 2021-09-24 | 纪念斯隆-凯特琳癌症中心 | 靶向b-细胞成熟抗原的抗体及其用途 |
| SG10201912819XA (en) | 2015-04-13 | 2020-02-27 | Pfizer | Therapeutic antibodies and their uses |
| FI3447075T3 (fi) | 2015-05-15 | 2023-11-07 | Massachusetts Gen Hospital | Antagonistisia anti-tuumorinekroositekijäreseptorin superperheen vasta-aineita |
| RS60030B1 (sr) | 2015-08-03 | 2020-04-30 | Engmab Sarl | Monoklonska antitela protiv humanog antigena sazrevanja b ćelija (bcma) |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| JP2018525005A (ja) | 2015-08-17 | 2018-09-06 | ヤンセン ファーマシューティカ エヌ．ベー． | 抗ｂｃｍａ抗体、ｂｃｍａ及びｃｄ３に結合する二重特異性抗原結合分子、並びにそれらの使用 |
| EP3374396A1 (en) | 2015-11-13 | 2018-09-19 | The United States of America, as represented by the secretary, Department of Health and Human Services | Anti-bcma polypeptides and proteins |
| RU2018123717A (ru) | 2015-12-01 | 2020-01-14 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Комбинированные лечения, их применения и способы |
| SG11201805770UA (en) | 2016-02-03 | 2018-08-30 | Amgen Res Munich Gmbh | BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs |
| CA3011900A1 (en) | 2016-02-17 | 2017-08-24 | Seattle Genetics, Inc. | Bcma antibodies and use of same to treat cancer and immunological disorders |
| AU2017240150C1 (en) | 2016-04-01 | 2022-10-27 | Kite Pharma, Inc. | BCMA binding molecules and methods of use thereof |
| WO2018151817A2 (en) | 2017-02-17 | 2018-08-23 | Unum Therapeutics Inc. | Co-use of anti-bcma antibody and antibody-coupled t celll receptor (actr) in cancer therapy and b cell disorders |
| KR20230005163A (ko) * | 2020-03-26 | 2023-01-09 | 씨젠 인크. | 다발성 골수종 치료 방법 |
-
2017
- 2017-02-16 CA CA3011900A patent/CA3011900A1/en active Pending
- 2017-02-16 CN CN202211055564.6A patent/CN116063503A/zh active Pending
- 2017-02-16 MA MA044254A patent/MA44254A/fr unknown
- 2017-02-16 CN CN201780011604.8A patent/CN108778329B/zh active Active
- 2017-02-16 WO PCT/US2017/018177 patent/WO2017143069A1/en not_active Ceased
- 2017-02-16 HK HK19101575.0A patent/HK1259075A1/zh unknown
- 2017-02-16 US US15/999,346 patent/US20190194338A1/en not_active Abandoned
- 2017-02-16 IL IL311107A patent/IL311107A/en unknown
- 2017-02-16 US US15/434,921 patent/US20170233484A1/en not_active Abandoned
- 2017-02-16 SG SG10202007836WA patent/SG10202007836WA/en unknown
- 2017-02-16 MX MX2018009700A patent/MX2018009700A/es unknown
- 2017-02-16 SG SG11201806261XA patent/SG11201806261XA/en unknown
- 2017-02-16 AU AU2017219747A patent/AU2017219747B2/en active Active
- 2017-02-16 JP JP2018543153A patent/JP7152309B2/ja active Active
- 2017-02-16 KR KR1020187021211A patent/KR102816905B1/ko active Active
- 2017-02-16 EP EP17753839.4A patent/EP3416687A4/en active Pending
- 2017-02-16 BR BR112018016697A patent/BR112018016697A2/pt unknown
- 2017-02-16 IL IL260732A patent/IL260732B2/en unknown
-
2018
- 2018-08-09 MX MX2023000889A patent/MX2023000889A/es unknown
- 2018-10-03 US US16/151,012 patent/US20190023801A1/en not_active Abandoned
-
2019
- 2019-05-14 US US16/411,867 patent/US11078291B2/en active Active
-
2020
- 2020-02-17 JP JP2020024261A patent/JP2020073605A/ja active Pending
-
2021
- 2021-06-25 US US17/358,642 patent/US11767365B2/en active Active
-
2022
- 2022-03-01 JP JP2022030779A patent/JP2022069488A/ja not_active Withdrawn
-
2023
- 2023-08-15 US US18/449,876 patent/US20240109975A1/en not_active Abandoned
- 2023-12-14 AU AU2023282281A patent/AU2023282281A1/en active Pending
- 2023-12-22 JP JP2023216464A patent/JP2024019677A/ja active Pending